Status:
COMPLETED
Brimonidine vs ALTP in Progressing Human Glaucoma
Lead Sponsor:
University of Parma
Conditions:
Glaucoma
Eligibility:
All Genders
50-70 years
Phase:
PHASE4
Brief Summary
This study is evaluating possible non-intraocular pressure (IOP) related effects of the alpha-1 agonist brimonidine in human subjects affected by a progressive glaucomatous optic neuropathy. Brimonidi...
Detailed Description
Patients with open angle glaucoma and a history of relative stability of the visual field are followed for 18 months. A visual field is measured every 3 months for a total number of n = 6 eligible fie...
Eligibility Criteria
Inclusion
- Glaucomatous visual field defect on achromatic perimetry (24/2 Humphrey full threshold,abnormal GHT and CPSD, p\<0.01) considered clinically "unstable"
- IOP \< 20 mmHg on repeated readings with no more than 2 medications,
- Open angle on gonioscopy,
- Glaucomatous optic neuropathy (HRTII, Moorfields regression analysis),
- Clear lens (LOCS2 score \< C1, N0, P0)
- Best corrected visual acuity better than 0.2 LogMAR (ETDRS chart),
- No previous bulbar surgery
- Manifest refraction within - 5 and + 2 diopters
- No comorbidity (AMD and diabetic retinopathy.and negative history for neurological diseases)
Exclusion
- Closed angle
- Previous bulbar surgery
- Unstable IOP
- Unreliable visual fields on historic data
Key Trial Info
Start Date :
August 1 1999
Trial Type :
INTERVENTIONAL
End Date :
October 1 2002
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00466479
Start Date
August 1 1999
End Date
October 1 2002
Last Update
April 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
sezione di Oftalmologia
Parma, Italy, 43100